EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

CURRENT MOLECULAR MEDICINE is a pivotal journal fostering advancements in the interdisciplinary fields of molecular medicine, biochemistry, and genetics. Published by Bentham Science Publishers, this esteemed journal has been disseminating vital research findings since its inception in 2001 and is continuously dedicated to exploring the molecular basis of health and disease. With a focus on translational research, CURRENT MOLECULAR MEDICINE provides an invaluable platform for researchers, healthcare professionals, and students, making significant contributions to the understanding of molecular mechanisms and therapeutic strategies. With an ISSN of 1566-5240 and an E-ISSN of 1875-5666, the journal holds a commendable position within the scientific community, being ranked Q3 in Biochemistry and Molecular Biology and Q2 in Medicine (miscellaneous) as of 2023. This journal does not currently operate on an open access model but remains accessible through various institutional subscriptions. The multidisciplinary scope covering molecular biology to medicinal applications positions CURRENT MOLECULAR MEDICINE as an essential resource for those striving to meet the challenges of modern healthcare and biomedical research.

BIOMEDICINE & PHARMACOTHERAPY is a distinguished journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, specializing in the essential fields of medicine and pharmacology. Established in 1982 and covering literature up to 2024, this journal is notably recognized for its impact, holding a prestigious Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, as well as a commendable position within the top 10% of its category based on Scopus rankings. Researchers and practitioners will find it serves as a vital resource for the latest advancements, innovations, and critical reviews in the life sciences and therapeutic practices. The journal emphasizes rigorous peer review and high-quality publications, aimed at facilitating knowledge dissemination in biomedicine and pharmacotherapy. Its commitment to excellence makes it an indispensable platform for contributors and readers alike who are engaged in improving health outcomes through pharmaceutical research and medical advances.

MOLECULAR AND CELLULAR BIOLOGY, published by TAYLOR & FRANCIS INC, stands as a preeminent platform for researchers, professionals, and students engaged in the dynamic field of molecular and cellular biology. Established in 1981 and ongoing into 2024, the journal features cutting-edge research that spans across vital sub-disciplines, garnering a strong impact in its contributions to the scientific community. With an impressive Q2 ranking in Cell Biology and Q1 ranking in Molecular Biology for 2023, it consistently publishes high-quality articles that reflect the latest advancements and discoveries within the field. The journal is particularly well-regarded for its rigorous peer-review process and commitment to scientific excellence, making it an invaluable resource for those seeking to deepen their understanding of molecular mechanisms and cellular processes. Although not open access, the journal offers diverse access options for researchers to reach the latest findings. By maintaining a strong focus on biochemistry, genetics, and molecular biology, MOLECULAR AND CELLULAR BIOLOGY remains essential reading for anyone looking to contribute to or stay informed about significant developments within this pivotal area of study.

International Journal of Molecular and Cellular Medicine, published by the CELLULAR & MOLECULAR BIOLOGY RESEARCH CENTER in Iran, is a leading platform dedicated to advancing research in various domains of molecular and cellular sciences. With an ISSN of 2251-9637 and E-ISSN 2251-9645, this journal features a rigorous peer-review process that ensures the publication of high-quality, impactful research. Spanning from 2016 to 2024, it is categorized in the third quartile (Q3) in Biochemistry, Cell Biology, Genetics, and Molecular Biology, and second quartile (Q2) in Biotechnology, underlining its significance in the scientific community. Although currently non-open access, it maintains credible visibility through Scopus rankings, reflecting its importance in fields such as Biochemistry, Molecular Medicine, and Genetics, where it holds respectable ranks and percentiles. This journal aims to foster collaboration and knowledge dissemination among researchers, professionals, and students in the pursuit of enhancing understanding and innovation in molecular and cellular medicine.

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.

Organogenesis is a leading journal published by Taylor & Francis Inc, dedicated to advancing the field of developmental biology and regenerative medicine. With an ISSN of 1547-6278 and E-ISSN 1555-8592, this journal spans an extensive research scope that includes embryology, transplantation, and biomedical engineering, distinguishing itself as a crucial platform for researchers and practitioners alike. Its impact is reflected in its performance across various categories in 2023, earning Q3 rankings in Biomedical Engineering and Embryology, Q4 in Developmental Biology, and Q2 in Transplantation, showcasing its reputable standing among peer journals. Moreover, with Scopus rankings indicating strong positioning in the fields of medicine and biochemistry, Organogenesis is essential for those looking to publish or stay updated on pioneering research. The journal facilitates rigorous peer-review and offers a forum for disseminating innovative findings, making it an invaluable resource for academics, professionals, and students committed to understanding the complexities of organism development.

EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.